Sichuan Kelun Pharmaceutical Co., Ltd.

SZSE:002422 Stock Report

Market Cap: CN¥44.2b

Sichuan Kelun Pharmaceutical Balance Sheet Health

Financial Health criteria checks 6/6

Sichuan Kelun Pharmaceutical has a total shareholder equity of CN¥26.2B and total debt of CN¥5.2B, which brings its debt-to-equity ratio to 19.7%. Its total assets and total liabilities are CN¥38.4B and CN¥12.2B respectively. Sichuan Kelun Pharmaceutical's EBIT is CN¥4.3B making its interest coverage ratio -40.6. It has cash and short-term investments of CN¥7.1B.

Key information

19.7%

Debt to equity ratio

CN¥5.16b

Debt

Interest coverage ratio-40.6x
CashCN¥7.08b
EquityCN¥26.23b
Total liabilitiesCN¥12.16b
Total assetsCN¥38.39b

Recent financial health updates

Recent updates

Why Investors Shouldn't Be Surprised By Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E

Dec 23
Why Investors Shouldn't Be Surprised By Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E

Here's Why Sichuan Kelun Pharmaceutical (SZSE:002422) Has Caught The Eye Of Investors

Nov 17
Here's Why Sichuan Kelun Pharmaceutical (SZSE:002422) Has Caught The Eye Of Investors

Sichuan Kelun Pharmaceutical (SZSE:002422) Has A Rock Solid Balance Sheet

Oct 28
Sichuan Kelun Pharmaceutical (SZSE:002422) Has A Rock Solid Balance Sheet

Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E No Reason For Excitement

Sep 22
Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Low P/E No Reason For Excitement

Should You Be Adding Sichuan Kelun Pharmaceutical (SZSE:002422) To Your Watchlist Today?

Aug 16
Should You Be Adding Sichuan Kelun Pharmaceutical (SZSE:002422) To Your Watchlist Today?

Is Sichuan Kelun Pharmaceutical (SZSE:002422) Using Too Much Debt?

Jul 12
Is Sichuan Kelun Pharmaceutical (SZSE:002422) Using Too Much Debt?

Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Prospects Need A Boost To Lift Shares

Jun 11
Sichuan Kelun Pharmaceutical Co., Ltd.'s (SZSE:002422) Prospects Need A Boost To Lift Shares

An Intrinsic Calculation For Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Suggests It's 45% Undervalued

May 21
An Intrinsic Calculation For Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Suggests It's 45% Undervalued

Sichuan Kelun Pharmaceutical's (SZSE:002422) Earnings Are Weaker Than They Seem

May 02
Sichuan Kelun Pharmaceutical's (SZSE:002422) Earnings Are Weaker Than They Seem

If EPS Growth Is Important To You, Sichuan Kelun Pharmaceutical (SZSE:002422) Presents An Opportunity

Mar 19
If EPS Growth Is Important To You, Sichuan Kelun Pharmaceutical (SZSE:002422) Presents An Opportunity

Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Mar 04
Sichuan Kelun Pharmaceutical Co., Ltd. (SZSE:002422) Surges 25% Yet Its Low P/E Is No Reason For Excitement

These 4 Measures Indicate That Sichuan Kelun Pharmaceutical (SZSE:002422) Is Using Debt Safely

Feb 27
These 4 Measures Indicate That Sichuan Kelun Pharmaceutical (SZSE:002422) Is Using Debt Safely

Financial Position Analysis

Short Term Liabilities: 002422's short term assets (CN¥19.1B) exceed its short term liabilities (CN¥10.1B).

Long Term Liabilities: 002422's short term assets (CN¥19.1B) exceed its long term liabilities (CN¥2.0B).


Debt to Equity History and Analysis

Debt Level: 002422 has more cash than its total debt.

Reducing Debt: 002422's debt to equity ratio has reduced from 78% to 19.7% over the past 5 years.

Debt Coverage: 002422's debt is well covered by operating cash flow (84.6%).

Interest Coverage: 002422 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 19:08
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sichuan Kelun Pharmaceutical Co., Ltd. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Jin ZhangChina International Capital Corporation Limited
Ziyu HeChina International Capital Corporation Limited